Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements.
More information about the transition.
Journal ArticleAdv Ther · April 2026
INTRODUCTION: Oral selexipag is indicated to delay disease progression and reduce risk of pulmonary arterial hypertension (PAH)-related hospitalization, as demonstrated in GRIPHON. There are situations when clinicians or patients may need or want to transi ...
Full textLink to itemCite
Journal ArticleAm J Med Open · June 2025
BACKGROUND: Returning results to research participants is increasingly recognized as an ethical mandate, yet little is known about best practices to optimally communicate urgent or emergent results. METHODS: We describe the development of and experience wi ...
Full textLink to itemCite
Journal ArticleJHLT Open · November 2024
BACKGROUND: Patients with pulmonary arterial hypertension (PAH) and additional cardiac or pulmonary comorbidities have a poor prognosis and are frequently excluded from clinical trials. The purpose of this study was to evaluate outcomes of patients with pu ...
Full textOpen AccessLink to itemCite
Journal ArticleESC Heart Fail · February 2024
In this case series, we describe the use of invasive cardiopulmonary exercise testing (iCPET) to diagnose heart failure due to preload reserve failure in two patients with progressive dyspnoea. We demonstrate that underlying liver disease contributes to pr ...
Full textLink to itemCite
Journal ArticleCurrent Respiratory Medicine Reviews · January 1, 2024
While the majority of patients have complete resolution of their acute pulmonary embolism (PE) after an adequate course of anticoagulation, some patients remain symptomatic with evidence of chronic PE. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) ...
Full textCite
ConferenceAm Heart J · September 2023
BACKGROUND: Electronic health record (EHR)-based identification of heart failure with preserved ejection fraction (HFpEF) in the clinical setting may facilitate screening for clinical trials by improving the understanding of its epidemiology and outcomes; ...
Full textLink to itemCite
Journal ArticleEur Heart J · June 1, 2023
AIMS: Severe tricuspid regurgitation (TR) exhibits high 1-year morbidity and mortality, yet long-term cardiovascular risk overall and by subgroups remains unknown. This study characterizes 5-year outcomes and identifies distinct clinical risk profiles of s ...
Full textLink to itemCite
Journal ArticleLancet · March 19, 2022
BACKGROUND: Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduc ...
Full textLink to itemCite
Journal ArticleJACC Basic Transl Sci · November 2021
Although there is an established bidirectional relationship between heart failure with reduced ejection fraction and liver disease, the association between heart failure with preserved ejection fraction (HFpEF) and liver diseases, such as nonalcoholic fatt ...
Full textLink to itemCite
Journal ArticleJ Card Fail · September 2021
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) continues to increase in prevalence with a 50% mortality rate within 3 years of diagnosis, but lacking effective evidence-based therapies. Specific echocardiographic markers are not typical ...
Full textLink to itemCite
Journal ArticleRespir Res · November 19, 2020
BACKGROUND: Multiple classes of oral therapy are available for the treatment of pulmonary arterial hypertension (PAH), but there is little to guide clinicians in choosing a specific regimen or therapeutic class. We aimed to investigate whether treatment-re ...
Full textOpen AccessLink to itemCite
Journal ArticleJACC Case Rep · November 18, 2020
In the COVID-19 era, the heart failure community has witnessed an unprecedented reduction in heart failure-related patient visits and hospitalizations. Social distancing measures present a dilemma for patients with heart failure who require frequent survei ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Heart Lung Transplant · September 2020
BACKGROUND: The age of patients with pulmonary arterial hypertension (PAH) has increased, with registries now reporting mean ages of 50 to 65 years old. Limited data exist on age-related differences in hemodynamic and functional assessments in PAH. METHODS ...
Full textLink to itemCite
Journal ArticleAm J Kidney Dis · May 2020
RATIONALE & OBJECTIVE: Pulmonary hypertension (PH) contributes to cardiovascular disease and mortality in patients with chronic kidney disease (CKD), but the pathophysiology is mostly unknown. This study sought to estimate the prevalence and consequences o ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Cardiovasc Pharmacol · April 2020
Parenteral prostacyclin therapies remain first-line therapy for patients with pulmonary arterial hypertension (PAH) with class IV symptoms. In selected patients who have been clinically stabilized, switching to selexipag, a chemically distinct prostacyclin ...
Full textOpen AccessLink to itemCite
Journal ArticleChest · December 2019
BACKGROUND: Pulmonary arterial hypertension (PAH) is a chronic disease that ultimately progresses to right-sided heart failure (HF) and death. Close monitoring of pulmonary artery pressure (PAP) and right ventricular (RV) function allows clinicians to appr ...
Full textOpen AccessLink to itemCite
Journal ArticleEur Respir J · December 2019
BACKGROUND: As an increasing number of patients exhibit concomitant cardiac and pulmonary disease, limitations of standard diagnostic criteria are more frequently encountered. Here, we apply noninvasive 129Xe magnetic resonance imaging (MRI) and spectrosco ...
Full textOpen AccessLink to itemCite
Journal ArticleJACC Heart Fail · December 2019
OBJECTIVES: This study sought to determine whether age modifies the impact of key comorbidities on clinical outcomes for patients with heart failure with reduced ejection fraction (HFrEF). BACKGROUND: Comorbidities impact outcomes in HFrEF. However, the ef ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · October 15, 2019
Echocardiography is a key tool in the management of patients with pulmonary arterial hypertension (PAH), but many potential parameters could be used to assess response to therapy. In this retrospective study of 48 patients with severe PAH at baseline, we e ...
Full textLink to itemCite
Journal ArticleRespir Med · April 2019
BACKGROUND: The clinical characteristics, hemodynamic changes and outcomes of lung disease-associated pulmonary hypertension (LD-PH) are poorly defined. METHODS: A prospective cohort of PH patients undergoing initial hemodynamic assessment was collected, f ...
Full textLink to itemCite
Journal ArticleSci Rep · March 11, 2019
The presence of pulmonary hypertension (PH) significantly worsens outcomes in patients with advanced sarcoidosis, but its optimal management is unknown. We aimed to characterize a large sarcoidosis-associated pulmonary hypertension (SAPH) cohort to better ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Heart Fail · January 2019
BACKGROUND: Hospitalizations for acute heart failure (HF) are significant events with downstream implications for patients, as well as healthcare systems and payers. However, from anecdotal experience, both hospitalization and postdischarge courses vary si ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 1, 2018
We aimed to study whether jugular venous distension (JVD) and peripheral edema were associated with worse outcomes in patients with acute heart failure in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial. Of 7,14 ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · August 2018
The number of persons with heart failure has continued to rise over the last several years. Approximately one-half of those living with heart failure have heart failure with preserved ejection fraction, but critical unsolved questions remain across the spe ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Genom Precis Med · August 2018
Background In heart failure (HF) with reduced ejection fraction, 2 clinical trials, the BEST (β-Blocker Evaluation of Survival Trial) and HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), have reported an effectiven ...
Full textLink to itemCite
Journal ArticleInt J Cardiovasc Imaging · July 2018
Acute decompensated heart failure (ADHF) is a common reason for admission to the hospital, and readmission is frequent. Multiple factors contribute to rehospitalizations, but inadequate assessment of volume status leading to persistent congestion is an imp ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2018
BACKGROUND: Chronic lower extremity venous disease (LECVD) is twice as prevalent as coronary heart disease, and invasive therapies to treat LECVD accounted for an estimated $290 million in Medicare expenditures in 2015. Despite increasing use of these inva ...
Full textLink to itemCite
Journal ArticleCurr Heart Fail Rep · December 2017
PURPOSE OF REVIEW: We explore the pharmacogenomics of the beta-blocker bucindolol by discussing relevant beta-1 adrenergic receptor (ADRB1) polymorphisms and recent beta-blocker studies. Through this, we will understand how bucindolol may help patients wit ...
Full textLink to itemCite
Journal ArticleEpidemiology · September 2017
BACKGROUND: The Jackson Heart Study (JHS) assesses cardiovascular disease risk factors among African Americans in Jackson, Mississippi. Whether characteristics of JHS participants differ from those of a broader African American population are unknown. METH ...
Full textLink to itemCite
Journal ArticleAm J Manag Care · August 2017
OBJECTIVES: Pulmonary hypertension portends a poorer prognosis for blacks versus white populations, but the underlying reasons are poorly understood. We investigated associations of disease characteristics, insurance status, and race with clinical outcomes ...
Open AccessLink to itemCite
Journal ArticleJ Am Coll Cardiol · April 4, 2017
BACKGROUND: The safety and efficacy of aerobic exercise in heart failure (HF) patients with atrial fibrillation (AF) has not been well evaluated. OBJECTIVES: This study examined whether outcomes with exercise training in HF vary according to AF status. MET ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · February 1, 2017
IMPORTANCE: Increased resting heart rate is associated with worse outcomes in studies of mostly white populations, but its significance is not well established in African Americans persons whose cardiac comorbidities and structural abnormalities differ. OB ...
Full textLink to itemCite
Journal ArticlePulm Circ · 2017
Pulmonary arterial hypertension (PAH) patients have distinct disease courses and responses to treatment, but current diagnostic and treatment schemes provide limited insight. We aimed to see if cluster analysis could distinguish clinical phenotypes in PAH. ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · October 15, 2016
Angina pectoris (AP) is associated with worse outcomes in heart failure (HF). We investigated the association of AP with health-related quality of life (HRQoL), exercise capacity, and clinical outcomes and its interaction with exercise training in an HF po ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Pharmacol · April 2016
Pulmonary arterial hypertension (PAH) has emerging therapeutic options including prostacyclin analogs. Inhaled therapy offers advantages compared with alternative routes of administration. We aimed to determine the safety and tolerability of inhaled trepro ...
Full textLink to itemCite
Journal ArticleJ Invasive Cardiol · April 2016
BACKGROUND AND PURPOSE: This study sought to investigate demographic, clinical, and procedural determinants of outcomes in patients treated with percutaneous veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) initiated in the cardiac catheteriza ...
Link to itemCite
Journal ArticleBMJ Case Rep · February 1, 2016
Infective endocarditis (IE) affects the pulmonic valve in less than 2% of cases. Not only is pulmonary valve IE rare, it is also challenging to visualise with commonly used imaging modalities. In this vignette, we present a 50-year-old patient with a histo ...
Full textLink to itemCite
Journal ArticleCirc J · 2016
Heart failure continues to be a leading cause of hospitalization worldwide, and acute heart failure (AHF) carries significant risk for short-term morbidity and mortality. Despite many trials of potential new therapies for AHF, there have been very few adva ...
Full textLink to itemCite
Journal ArticleASAIO J · 2016
Left heart disease (LHD) represents the most common cause of pulmonary hypertension (PH), and is associated with worse prognosis compared with LHD without PH. In addition, PH due to LHD may prevent patients from receiving heart transplantation, because of ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2015
OBJECTIVES: To evaluate the use of surrogate measures in pulmonary hypertension (PH) clinical trials and how it relates to clinical practice. BACKGROUND: Studies of pulmonary arterial hypertension (PAH) employ a variety of surrogate measures in addition to ...
Full textLink to itemCite
Journal ArticleHeart Fail Clin · October 2014
Pharmacogenomics explores one drug's varying effects on different patient genotypes. A better understanding of genomic variation's contribution to drug response can impact 4 arenas in heart failure (HF): (1) identification of patients most likely to receiv ...
Full textLink to itemCite
Journal ArticleJ Mol Med (Berl) · October 2013
UNLABELLED: The rapid growth of cancer cells is permitted by metabolic changes, notably increased aerobic glycolysis and increased glutaminolysis. Aerobic glycolysis is also evident in the hypertrophying myocytes in right ventricular hypertrophy (RVH), par ...
Full textLink to itemCite
Journal ArticleJ Mol Med (Berl) · March 2013
Pyruvate dehydrogenase kinase (PDK) is activated in right ventricular hypertrophy (RVH), causing an increase in glycolysis relative to glucose oxidation that impairs right ventricular function. The stimulus for PDK upregulation, its isoform specificity, an ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · January 2013
OBJECTIVES: This study sought to assess the effectiveness of a novel percutaneous method to treat left ventricular assist device (LVAD)-associated severe aortic insufficiency (AI) in a series of patients determined to be poor reoperative candidates. BACKGR ...
Full textLink to itemCite
Journal ArticleCirculation · December 11, 2012
BACKGROUND: The cause and consequences of impaired adrenergic signaling in right ventricular failure/hypertrophy (RVH) are poorly understood. We hypothesized that G protein-coupled receptor kinase-2 (GRK2)-mediated uncoupling of β-adrenergic receptor signa ...
Full textLink to itemCite
Journal ArticleAm J Emerg Med · January 2012
The diagnosis of acute coronary syndrome relies on clinical history, electrocardiographic (ECG) changes, and cardiac biomarkers; but within the spectrum of acute coronary syndrome, there exist subtle presentations that cannot afford to be overlooked. Welle ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · October 2010
BACKGROUND: Early repolarization, indicated on the standard 12-lead ECG, has recently been associated with idiopathic ventricular fibrillation in patients without structural heart disease. It is unknown whether there is an association between early repolar ...
Full textLink to itemCite
Journal ArticleCancer Genet Cytogenet · December 2004
Array-comparative genomic hybridization (a-CGH) is a molecular cytogenetic technique for detection of multiple chromosomal abnormalities in genomic DNA samples. Using an a-CGH with 287 probes, we examined 14 cases of breast infiltrating ductal carcinoma (I ...
Full textLink to itemCite